Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5):327-31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5):327-31

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: Italian

Vernakalant: a new drug for the treatment of atrial fibrillation

Incardona V. M., Dato E., Dato A. G.

Centro di Diagnostica Cardiovascolare del Dott. Dato Achille Giuseppe & C. s.a.s., Paternò, Italia


PDF


Vernakalant (RSD1235) is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels: the Kv1.5 channel which carries IK(ur), and the Kir3.1/3.4 channel which carries IK(Ach). Vernakalant can to block Ito, late Ina, with minor blockade of IKr currents. Vernakalant is available in intravenous forms and in oral forms. In phase II and III trials, intravenous vernakalant has been shown to be effective in terminating acute onset atrial fibrillation (AF) whose duration is longer than 3 hours and shorter than 7 days. Studies to date have shown that 51% of patients were able to maintain sinus rhythm after 90 days of using oral vernakalant 50 mg/kg twice daily compared with 37% of patients receiving placebo. Vernakalant appears to be a safe drug to use, with a few side-effects being dysgeusia, paresthesias, nausea but a minimal frequency of ventricular arrhythmias.

top of page